Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for leukaemia significantly...
Vous n'êtes pas connecté
- NEWS.MEDICAL.NET - A la Une - 10/Feb 13:57
Novel MSC-based therapy provides hope for ocular GVHD treatment
Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the donor's immune cells attack the recipient's tissues.
Articles similaires
Inflammatory cells may persist despite biologic therapy in severe asthma
news.medical.net - 26/Jun 13:24
Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet in Sweden shows that some...
Diabetic woman no longer needs insulin after single stem cell treatment — why it’s not ...
wn.com - 24/Jun 07:25
A Canadian nurse has kicked insulin to the curb after just one dose of an experimental stem cell therapy, with experts calling it a milestone in the...
Diabetic woman no longer needs insulin after single stem cell treatment — why it’s not ...
wn.com - 24/Jun 07:25
A Canadian nurse has kicked insulin to the curb after just one dose of an experimental stem cell therapy, with experts calling it a milestone in the...
COVID-19 protein triggers immune attacks on healthy cells — but a common drug can stop it
wn.com - 24/Jun 18:23
Scientists have uncovered a stealthy tactic used by the SARS-CoV-2 virus: one of its proteins can leap from infected cells to healthy ones,...
COVID-19 protein triggers immune attacks on healthy cells — but a common drug can stop it
wn.com - 24/Jun 18:23
Scientists have uncovered a stealthy tactic used by the SARS-CoV-2 virus: one of its proteins can leap from infected cells to healthy ones,...
New dawn for NeuroScientific with stem cell acquisition
thewest.com.au - 27/Jun 02:55
NeuroScientific Biopharmaceuticals has ventured into stem cell therapy with a $5.1M purchase of unlisted Perth-based company Isopogen, whose tech...
New dawn for NeuroScientific with stem cell acquisition
thewest.com.au - 27/Jun 02:55
NeuroScientific Biopharmaceuticals has ventured into stem cell therapy with a $5.1M purchase of unlisted Perth-based company Isopogen, whose tech...
Limbal Stem Cells Deficiency Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Statistics, ...
wn.com - 01/Jul 00:10
"Limbal Stem Cells Deficiency Treatment Market" Limbal Stem Cells Deficiency Companies are Kala Pharmaceuticals, CLIPS BnC Co., Ltd, RHEACELL GmbH,...
Stem Cell Treatment May Free Some With Type 1 Diabetes From Insulin
drugs.com - 24/Jun 15:06
TUESDAY, June 24, 2025 — A single infusion of a new stem cell-based treatment may have helped 10 out of 12 people with severe type 1 diabetes...
Les derniers communiqués
-
Aucun élément